Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27471576 | 0.86 | TSHR (0.57) | TSHRLMNACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL18970231 | 0.85 | TSHR (0.56) | TSHRLMNACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL9163048 | 0.83 | TSHR (0.54) | TSHRLMNACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL18970233 | 0.83 | TSHR (0.54) | TSHRLMNACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL11910298 | 0.83 | TSHR (0.57) | TSHRLMNACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL22165229 | 0.82 | TSHR (0.53) | TSHRLMNACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL28369566 | 0.82 | CYP1A2 (0.54) | TSHRLMNACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL6986228 | 0.82 | TSHR (0.66) | TSHRLMNACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL30781045 | 0.82 | TSHR (0.61) | TSHRLMNACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL27323340 | 0.82 | TSHR (0.61) | TSHRLMNACYP1A2CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20210186970-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | NORTHWESTERN UNIVERSITY | 2021-06-24 | — | — | US | disclosed |
| US-10882871-B2 | 18/19F-labelled compounds which target the prostate specific membrane antigen | BRITISH COLUMBIA CANCER AGENCY BRANCH | 2021-01-05 | — | — | US | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| US-10458995-B2 | Combinatorial synthesis and biomarker development | TEN30 BIOSCIENCES, INC. | 2019-10-29 | — | — | US | disclosed |
| US-20190167685-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | NORTHWESTERN UNIVERSITY | 2019-06-06 | — | — | US | disclosed |
| US-20190113521-A1 | COMBINATORIAL SYNTHESIS AND BIOMARKER DEVELOPMENT | TEN30 BIOSCIENCES, INC. | 2019-04-18 | — | — | US | disclosed |
| US-10022371-B2 | Procaspase-activating compounds and methods | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170355700-A1 | PYRAZOLOPYRIMIDINE ANTIBACTERIAL AGENTS | NORTHERN ILLINOIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-20170355700-A1 | PYRAZOLOPYRIMIDINE ANTIBACTERIAL AGENTS | NORTHERN ILLINOIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| US-7319163-B2 | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | KARO BIO AB (SE) | 2008-01-15 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1112269-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015634-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
| EP-0935597-A2 | DIHYDROPYRONES WITH IMPROVED ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 1999-08-18 | — | — | EP | disclosed |
| WO-1998019997-A2 | DIHYDROPYRONES WITH IMPROVED ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167685-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | CACNA1C, CACNA1B, CACNA1G | TSHR 4014/4885LMNA 1316/4885CYP1A2 4681/4885 |
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | TSHR 3505/4885LMNA 293/4885CYP1A2 380/4885 |
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | TSHR 660/4885LMNA 4169/4885CYP1A2 424/4885 |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | TSHR 3798/4885LMNA 3691/4885CYP1A2 3312/4885 |
| US-10882871-B2 | 18/19F-labelled compounds which target the prostate specific membrane antigen | KLK3, FOLH1, FOLR1 | TSHR 1326/4885LMNA 3766/4885CYP1A2 3426/4885 |
| US-20170355700-A1 | PYRAZOLOPYRIMIDINE ANTIBACTERIAL AGENTS | DHPS, FDPS, IMPDH1 | TSHR 3838/4885LMNA 4005/4885CYP1A2 90/4885 |
| US-20190113521-A1 | COMBINATORIAL SYNTHESIS AND BIOMARKER DEVELOPMENT | APP, PSEN2, PSEN1 | TSHR 4495/4885LMNA 4106/4885CYP1A2 4771/4885 |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | DNMT3B, DNMT1, DNMT3L | TSHR 4203/4885LMNA 2261/4885CYP1A2 325/4885 |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | TSHR 211/4885LMNA 3390/4885CYP1A2 3253/4885 |
| US-10022371-B2 | Procaspase-activating compounds and methods | CASP3, CASP5, CASP6 | TSHR 4827/4885LMNA 294/4885CYP1A2 4269/4885 |
| US-10458995-B2 | Combinatorial synthesis and biomarker development | APP, PSEN2, PSEN1 | TSHR 4386/4885LMNA 4126/4885CYP1A2 4762/4885 |
| US-20210186970-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | CACNA1C, CACNA1B, CACNA1G | TSHR 4014/4885LMNA 1316/4885CYP1A2 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.